246 related articles for article (PubMed ID: 22843705)
1. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.
Kröller-Schön S; Knorr M; Hausding M; Oelze M; Schuff A; Schell R; Sudowe S; Scholz A; Daub S; Karbach S; Kossmann S; Gori T; Wenzel P; Schulz E; Grabbe S; Klein T; Münzel T; Daiber A
Cardiovasc Res; 2012 Oct; 96(1):140-9. PubMed ID: 22843705
[TBL] [Abstract][Full Text] [Related]
2. Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia.
Steven S; Hausding M; Kröller-Schön S; Mader M; Mikhed Y; Stamm P; Zinßius E; Pfeffer A; Welschof P; Agdauletova S; Sudowe S; Li H; Oelze M; Schulz E; Klein T; Münzel T; Daiber A
Basic Res Cardiol; 2015 Mar; 110(2):6. PubMed ID: 25600227
[TBL] [Abstract][Full Text] [Related]
3. Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin.
Lai ZW; Li C; Liu J; Kong L; Wen X; Sun H
Eur J Med Chem; 2014 Aug; 83():547-60. PubMed ID: 24996141
[TBL] [Abstract][Full Text] [Related]
4. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.
Schürmann C; Linke A; Engelmann-Pilger K; Steinmetz C; Mark M; Pfeilschifter J; Klein T; Frank S
J Pharmacol Exp Ther; 2012 Jul; 342(1):71-80. PubMed ID: 22493041
[TBL] [Abstract][Full Text] [Related]
5. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Tiwari A
Curr Opin Investig Drugs; 2009 Oct; 10(10):1091-104. PubMed ID: 19777398
[TBL] [Abstract][Full Text] [Related]
6. Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
Takai S; Sakonjo H; Jin D
J Pharmacol Sci; 2014; 125(4):386-93. PubMed ID: 25030743
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.
Kanasaki K; Shi S; Kanasaki M; He J; Nagai T; Nakamura Y; Ishigaki Y; Kitada M; Srivastava SP; Koya D
Diabetes; 2014 Jun; 63(6):2120-31. PubMed ID: 24574044
[TBL] [Abstract][Full Text] [Related]
8. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
Deacon CF; Holst JJ
Expert Opin Investig Drugs; 2010 Jan; 19(1):133-40. PubMed ID: 19947894
[TBL] [Abstract][Full Text] [Related]
9. DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure.
Koibuchi N; Hasegawa Y; Katayama T; Toyama K; Uekawa K; Sueta D; Kusaka H; Ma M; Nakagawa T; Lin B; Kim-Mitsuyama S
Cardiovasc Diabetol; 2014 Nov; 13():157. PubMed ID: 25471116
[TBL] [Abstract][Full Text] [Related]
10. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
Alter ML; Ott IM; von Websky K; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Klein T; Hocher B
Kidney Blood Press Res; 2012; 36(1):119-30. PubMed ID: 23171828
[TBL] [Abstract][Full Text] [Related]
11. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
12. Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats.
Retlich S; Withopf B; Greischel A; Staab A; Jaehde U; Fuchs H
Biopharm Drug Dispos; 2009 Nov; 30(8):422-36. PubMed ID: 19771584
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
[TBL] [Abstract][Full Text] [Related]
14. Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux.
Fuchs H; Runge F; Held HD
Eur J Pharm Sci; 2012 Apr; 45(5):533-8. PubMed ID: 22198311
[TBL] [Abstract][Full Text] [Related]
15. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats.
Hocher B; Sharkovska Y; Mark M; Klein T; Pfab T
Int J Cardiol; 2013 Jul; 167(1):87-93. PubMed ID: 22217485
[TBL] [Abstract][Full Text] [Related]
16. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Barnett AH
Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
[TBL] [Abstract][Full Text] [Related]
17. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity.
Yamagishi S; Ishibashi Y; Ojima A; Sugiura T; Matsui T
Int J Cardiol; 2014 Sep; 176(2):550-2. PubMed ID: 25065332
[No Abstract] [Full Text] [Related]
18. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
Forst T; Pfützner A
Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.
Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
Vascul Pharmacol; 2016 Apr; 79():16-23. PubMed ID: 26277250
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
